What happened
Published October 8, 2025 and highlighted again on October 1, 2026, KFF’s “Medicare 101” lays out the program’s current scale rather than a new policy action. Established in 1965 under Title XVIII of the Social Security Act, Medicare now provides health insurance coverage to 68 million people, including 61 million age 65 or older and 7 million under age 65. KFF says Medicare spending comprised 13.5% of the federal budget in 2024 and 21.2% of national health care spending in 2023. The piece also notes that most beneficiaries can choose traditional Medicare or Medicare Advantage private plans, while Medicare’s covered services include hospitalizations, physician visits, prescription drugs, post-acute care, skilled nursing facility care, home health care, hospice, and preventive services. On demographics and growth, KFF says the number of beneficiaries is projected to rise by more than one-third, from 68 million in 2024 to more than 93 million in 2060.
Why it matters
The analyst read is simple: Medicare is not just a public program. It is one of the core demand and reimbursement engines in U.S. healthcare. When a program accounts for 21.2% of national health care spending and 13.5% of the federal budget, even “introductory” facts become commercially material for drugmakers, PBMs, MA plans, and providers. For pharma, the practical implication is that Medicare exposure keeps moving from a policy footnote to a central planning assumption, especially in therapeutic areas tied to older adults and long-term chronic disease. For employer-side PBM benchmarking, see RxPBM.ai.
The second implication is demographic, not merely fiscal. KFF’s projection of more than 93 million beneficiaries by 2060, alongside an older and more diverse covered population, points toward sustained pressure on benefit design, utilization management, and affordability debates. That does not, by itself, dictate any single policy outcome. It does suggest Medicare will remain the reference market that shapes how stakeholders think about access, premiums, and drug coverage in 2026 and beyond. Investors and payer executives should keep watching where volume growth is concentrated and how the traditional Medicare versus Medicare Advantage mix evolves, because that mix can influence channel economics and formulary leverage. Detailed drug monographs are at ClinicalRx.ai.
